	US 11,718,666 B2
	Inhibitors of neuroligin 4-neurexin 1-beta protein-protein interaction for treatment of liver disorders
Rifaat Safadi, Nazareth Elit (IL)
Assigned to HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., Jerusalem (IL)
Filed by HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., Jerusalem (IL)
Filed on Jul. 29, 2021, as Appl. No. 17/388,218.
Application 16/407,848 is a division of application No. 15/562,602, abandoned, previously published as PCT/IL2016/050351, filed on Mar. 31, 2016.
Application 17/388,218 is a continuation of application No. 16/407,848, filed on May 9, 2019, granted, now 11,098,116.
Claims priority of provisional application 62/141,299, filed on Apr. 1, 2015.
Prior Publication US 2022/0010009 A1, Jan. 13, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61P 1/16 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 38/16 (2013.01); A61K 38/177 (2013.01); A61K 38/1709 (2013.01); A61P 1/16 (2018.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01)]

14 Claims

1. A method of treating, attenuating and/or preventing progression of a liver disorder, the method comprising administering a therapeutically effective amount of a recombinant NLGn4 (rNLGn4), capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4) — Neurexin 1β (Nrx1b) protein-protein interaction, wherein the rNLGn4 comprises the extracellular domain of NLGn4, and a pharmaceutically acceptable carrier, thereby treating, attenuating and/or preventing the progression of a liver disorder.